NCT06560333 - iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD) | Biotech Hunter

Enrollment

612

Participants

Timeline

Start Date

November 30, 2026

Primary Completion Date

April 30, 2027

Study Completion Date

February 28, 2029

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

N0892

1 tablet of Forxiga® 10mg, 1 tablet of Januvia® 100mg and 1 tablet of Glifage XR® 1000mg

DRUG

Januvia® + Glifage XR® + Placebo

1 tablet of Januvia® 100mg, 1 tablet of Glifage XR® 1000mg and 1 tablet of Placebo of Forxiga ®10mg

DRUG

Forxiga® + Glifage XR® + Placebo

1 tablet of Forxiga ®10mg, 1 tablet of Glifage XR® 1000mg and 1 tablet of Placebo of Januvia ® 100mg

Trial Locations (1)

Eurofarma Laboratorios S.A, São Paulo